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EDITORIAL COMMENT
Angiotensin-Converting Enzyme
Inhibitors: Ischemia Is Not
the Correct Measure of Benefit*
H. Vernon Anderson, MD, FACC
Houston, Texas
Many or even most patients with coronary disease and
chronic stable angina will obtain complete relief of symp-
toms with percutaneous coronary intervention (PCI) (1).
When coupled with appropriate management of cardiovas-
cular risk factors, PCI offers coronary patients the possibility
of long intervals of active, event-free lives. Nevertheless,
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some chronic angina patients are not able to benefit from
PCI. Personal choice may preclude a procedure, as may
technical features of the coronaries, for example, the pres-
ence of diffuse disease in small vessels, chronic occlusions, or
inability to treat all lesions (i.e., incomplete revasculariza-
tion). In these cases medical management of ischemia and
angina may be required.
MEDICATIONS FOR CHRONIC STABLE ANGINA
The recently published American College of Cardiology/
American Heart Association 2002 Guideline Update for
Management of Patients with Chronic Stable Angina con-
tains a comprehensive review of medications used for this
purpose (2). Three classes of agents reviewed (beta-blockers,
calcium antagonists, and nitrates) are effective for angina on
the basis of altering the supply-demand imbalance created
by flow-limiting coronary stenoses. These agents can reduce
heart rate, blood pressure, and coronary vascular resistance,
and redistribute coronary blood flow from subepicardial to
subendocardial regions. The net effect is reduction in
myocardial ischemia that leads to angina. The guideline
update very importantly also reviews three other classes of
agents used in chronic stable angina that affect fundamental
activities of the vascular endothelium, either by altering
endothelial cell function in certain favorable ways, or by
reducing “inflammation” (a series of cytokine and leukocyte
responses), or by preventing thrombosis. These other three
therapeutic classes are antiplatelet agents, lipid-lowering
agents (especially statins), and angiotensin-converting en-
zyme (ACE) inhibitors. The importance of these other
classes in addition to the traditional triad of beta-blockers,
calcium antagonists, and nitrates cannot be overstated.
VASCULAR ENDOTHELIUM
Aberrations in physiologic functioning of vascular endothe-
lium are involved in all stages of coronary atherothrombotic
disease: initiation of fatty streaks and their development into
plaques, plaque growth and progression, and, finally, dete-
rioration and degeneration with plaque rupture and acute
thrombosis. The endothelial dysfunction central to all this
can result from many causes, operating either alone or
together in concert. Traditional coronary risk factors such as
smoking, hypertension, diabetes, and elevated cholesterol all
produce endothelial dysfunction, and this likely is how they
each operate to increase coronary risk (3). Additionally,
chronic “inflammation” as a cause, or an effect, or perhaps
only a marker of endothelial dysfunction has been the focus
of increasing attention in recent years (4,5). But whatever
the multiplicity and interconnectedness of the causes, once
atherosclerosis has progressed to the point of forming one or
more flow-limiting stenoses, chronic stable angina may
ensue. This gives rise to the paradigm that chronic stable
angina could be viewed (at some level) as essentially a
vascular endothelial disorder.
ANGIOTENSIN
One of the key substances involved in regulating arterial
vascular function is angiotensin. Within vascular endothelial
cells, angiotensin interacts with various oxidases to reduce
the production of nitric oxide and increase the production of
reactive oxygen species like superoxide. This imbalance
reduces coronary vasodilator capacity, and promotes leuko-
cyte adhesion, vascular smooth muscle cell proliferation, and
platelet aggregation (6,7). Furthermore, angiotensin either
directly or indirectly interacts with lipoprotein oxidation
pathways to increase oxidized low-density lipoprotein, a
promoter of atherogenesis (8,9). The counterpoint to all of
this is that inhibition of angiotensin can ameliorate these
undesirable actions.
Clinically, angiotensin inhibition achieved by reducing its
formation (ACE inhibitors), or blocking its specific cell
surface receptors (angiotensin receptor blockers [ARBs]),
has been found beneficial in many abnormal cardiovascular
states or even in patients with only cardiovascular risk
factors. For instance, ACE inhibitors and ARBs are used to
treat hypertension, one of their traditional and most notable
applications. Furthermore, apart and separate from this,
ACE inhibitors and ARBs have been shown to reduce
adverse cardiovascular events and improve survival in pa-
tients with left ventricular dysfunction and heart failure, as
well as in patients after myocardial infarction and bypass
surgery. Some of these effects fall into the category of
secondary prevention, an area where statins are known to be
useful, and there is evidence of an additive effect of ACE
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inhibitors (quinapril, in fact) and ARBs on the anti-
inflammatory actions of statins (10). They have been shown
to slow the progression of both diabetic as well as nondia-
betic renal disease (11,12). These benefits appear unrelated
to the direct antihypertensive effects of these drugs, and it is
likely that changes in endothelial cell function (i.e., re-
establishing balance) are at least partly the way ACE
inhibitors and ARBs achieve this (6,13). Intriguingly, ACE
inhibitors recently have been shown to reduce the incidence
of atrial fibrillation in patients with left ventricular dysfunc-
tion, possibly by neurohormonal alterations, or reduction in
atrial pressure and stretch, or via a direct antiarrhythmic
effect (14). It is very likely that in the future the list of
potentially beneficial actions from angiotensin inhibition
will grow even longer.
CHRONIC ANGINA
Given the established clinical benefits of angiotensin inhi-
bition, and the putative mechanisms by which these benefits
arise, it was a natural extension to anticipate that ACE
inhibitors might also lead to reduced ischemia and angina in
the chronic stable state of coronary disease. The current
study reported in this issue of the Journal by Pepine et al.
(15) investigates this question. The Quinapril Anti-
ischemia and Symptoms of Angina Reduction (QUASAR)
trial randomly assigned 336 patients with stable coronary
disease to the ACE inhibitor quinapril or to placebo. None
of the patients had hypertension, left ventricular dysfunc-
tion, or other reasons for which ACE inhibitors are usually
indicated. Thus, the ACE inhibitor truly was an “addi-
tional” agent. Exercise treadmill testing, angina question-
naires, and ambulatory electrocardiogram (ECG) recordings
were done at baseline, 8 weeks, and 16 weeks. No significant
differences in ischemia were found, either in treadmill
measures or ambulatory measures of ischemia. The adverse
event rates were low in both groups. These results match
closely those from the QUO VADIS trial of 149 patients
with coronary disease randomized to quinapril or placebo
four weeks before elective bypass surgery and then followed
for one year (16). Exercise treadmill tests and Holter
monitors were used to measure ischemia at baseline and one
year. Just as in QUASAR, QUO VADIS found no differ-
ences in ischemic measures between the quinapril and
placebo groups. And yet, similar to other clinical trials of
ACE inhibitors, with the longer one year follow-up in
QUO VADIS, there were fewer adverse cardiovascular
events found in the quinapril-treated group compared with
the placebo-treated group: 4% versus 15% (p  0.02).
Unfortunately, the 16-week duration of the QUASAR trial
was likely too brief to find a difference in adverse events.
As the authors of the QUASAR trial point out, the
mechanisms leading to chronic exertional angina and re-
cordable ischemia are likely very different from those leading
to acute adverse clinical events, that is, fixed, flow-limiting
stenoses versus inflammation and sudden plaque rupture.
The coronary vasomotor activities that might affect variables
like duration of exercise treadmill time, ECG ST-segment
depression during exercise or on Holter monitoring, and the
like, probably are already modified by the traditional triad of
beta-blockers, calcium antagonists, and nitrates. Adding
ACE inhibitors to this successful regimen to reduce isch-
emia likely confers little benefit. Because the accumulated
clinical evidence does indicate, however, that ACE inhibi-
tors reduce adverse clinical events that are due to plaque
degeneration, the implications are that the influence of
these drugs lies elsewhere, and it is probably on inflamma-
tion and acute plaque disruption.
SUMMARY
The investigators in QUASAR have done us a favor and
now helped answer a persistently nagging question. Are
ACE inhibitors useful adjuncts to current therapy for
reducing daily ischemia in chronic stable coronary disease?
The answer is no. On the other hand, are ACE inhibitors
useful and beneficial agents for reducing adverse cardiovas-
cular events over the long term? The answer appears to be
yes, but the mechanism apparently is not by reducing daily
ischemia. So we must refocus our attention on other
possible mechanisms, and further studies will be needed to
unravel these. Inflammatory mediators, cytokines, and oxi-
dation products are promising candidates. Given the relative
safety of ACE inhibitors and ARBs, and their apparent
clinical benefit with long-term administration, it is likely
that the use of these agents will only increase in the years
ahead. With the recent redefinition of blood pressure goals
that have now created a “prehypertension” category, it is
exceedingly likely that many more adults will soon be using
these drugs (17). Understanding how and why they are
obtaining clinical benefits will be easier now that we have
these data indicating that control of chronic stable myocar-
dial ischemia is not the mechanism, and the proper way to
measure the benefit lies elsewhere.
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